a Multicenter Clinical Trial for the Treatment of Children and Adolescents With Soft Tissue Sarcoma Stage 4
- Conditions
- Sarcoma, Soft Tissue
- Registration Number
- NCT00130858
- Lead Sponsor
- Cooperative Weichteilsarkom Study Group
- Brief Summary
Phase II Study to evaluate the response on two blocks of topotecan and carboplatin
- Detailed Description
Phase II study for patients with chemosensible soft tissue sarcoma stage IV in children and adolescents ; response according to RECIST criteria following two blocks of combination therapy consisting of Topotecan and carboplatin
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 90
- Soft tissue sarcoma chemosensible, stage IV
- age < 21
- measurable tumor lesions
- Lack of cooperation by the patient
- no willingness of follow-up examinations
- participation on another clinical trial at the same time
- death due to the sickness within four weeks
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Response according to RECIST criteria
- Secondary Outcome Measures
Name Time Method Toxicity Overall-Survival Event-free-survival
Trial Locations
- Locations (33)
HELIOS Klinikum Erfurt GmbH
🇩🇪Erfurt, Sachsen, Germany
Zentralklinikum
🇩🇪Augsburg, Germany
Klinikum Berlin-Buch
🇩🇪Berlin, Germany
Virchow Klinik
🇩🇪Berlin, Germany
Zentrum für Kinderheilkunde
🇩🇪Bonn, Germany
Zentralkrankenhaus Bremen
🇩🇪Bremen, Germany
Universitätsklinik der technischen Universität Dresden
🇩🇪Dresden, Germany
Heinrich-Heine-Universität
🇩🇪Düsseldorf, Germany
Universitätsklinik für Kinderund Jugendliche
🇩🇪Erlangen, Germany
Universitätsklinikum Essen
🇩🇪Essen, Germany
Scroll for more (23 remaining)HELIOS Klinikum Erfurt GmbH🇩🇪Erfurt, Sachsen, Germany